Clinical Trial Detail

NCT ID NCT03457948
Title Pembrolizumab and Liver-Directed Therapy in Treating Patients With Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Liver Metastases
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of California, San Francisco
Indications

neuroendocrine tumor

Therapies

Pembrolizumab

Pembrolizumab + Yttrium-90

Age Groups: adult senior

No variant requirements are available.